Novel Biotech Company Shows Promising Myelofibrosis Treatment

Galecto's MYLOX-1 Trial Shows Promising Results in Myelofibrosis Patients.

Galecto, a biotechnology company focused on the development of novel treatments for fibrosis and cancer, recently announced positive top-line results from its MYLOX-1 trial. The trial demonstrated a reduction in fibrosis of the bone marrow in patients with myelofibrosis, a rare type of bone marrow cancer that disrupts your body's normal production of bl…